| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2026 ( Subtotal = $19,084,679 ) (Continued on the next page) |
| | 2026 | 2026 | JOSLIN DIABETES CENTER, INC. | 1 JOSLIN PL | BOSTON | MA | 02215-5306 | SUFFOLK | USA | R01AG054215 | Homeostasis functions of SKN-1A/Nrf1 | 000 | 9 | NIH | 5/7/2026 | $525,247 |
| | 2026 | 2026 | JOSLIN DIABETES CENTER, INC. | 330 BROOKLINE AVE | BOSTON | MA | 02215-5400 | SUFFOLK | USA | K23DK134877 | Precision Monitoring: Understanding Momentary Affect, Glucose, and Self-care Behaviors in Adolescents and Young Adults with type 1 diabetes | 000 | 4 | NIH | 7/27/2026 | $190,209 |
| | 2026 | 2026 | JOSLIN DIABETES CENTER, INC. | 330 BROOKLINE AVE | BOSTON | MA | 02215-5400 | SUFFOLK | USA | R01DK146036 | Investigating the Mechanistic Role of Brown Fat-derived Lipid Mediators and Their Analogs in Metabolic Health | 000 | 1 | NIH | 8/26/2026 | $868,285 |
| | 2026 | 2026 | JOSLIN DIABETES CENTER, INC. | 330 BROOKLINE AVE | BOSTON | MA | 02215-5400 | SUFFOLK | USA | K01DK142001 | Drivers of Human Insulin Resistance and Sex-specific Alterations | 000 | 2 | NIH | 7/28/2026 | $149,083 |
| | 2026 | 2026 | JOSLIN DIABETES CENTER, INC. | 1 JOSLIN PL | BOSTON | MA | 02215-5306 | SUFFOLK | USA | R01AG096437 | Evaluating clinical and pathological markers of cognitive decline and Alzheimer's dementia in long-duration type 1 diabetes. | 000 | 2 | NIH | 5/4/2026 | $629,622 |
| | 2026 | 2026 | JOSLIN DIABETES CENTER, INC. | 1 JOSLIN PL | BOSTON | MA | 02215-5306 | SUFFOLK | USA | U01DK143496 | Targeting Renalase for early stage T1D treatment | 000 | 1 | NIH | 4/9/2026 | $826,321 |
| | 2026 | 2026 | JOSLIN DIABETES CENTER, INC. | 1 JOSLIN PL | BOSTON | MA | 02215-5306 | SUFFOLK | USA | K23DK137024 | Development of an intervention to target diabetes device use through an identity framework: ACCPTech (Adapt and Commit to CGM and Pump Technology) | 000 | 3 | NIH | 3/24/2026 | $188,784 |
| | 2026 | 2026 | JOSLIN DIABETES CENTER, INC. | 330 BROOKLINE AVE | BOSTON | MA | 02215-5400 | SUFFOLK | USA | U01DK116102 | 9/14 APOL1 Long-term Kidney Transplantation Outcomes Network (APOLLO) Clinical Center | 002 | 8 | NIH | 7/29/2026 | $0 |
| | 2026 | 2026 | JOSLIN DIABETES CENTER, INC. | 330 BROOKLINE AVE | BOSTON | MA | 02215-5400 | SUFFOLK | USA | U01DK116102 | 9/14 APOL1 Long-term Kidney Transplantation Outcomes Network (APOLLO) Clinical Center | 002 | 8 | NIH | 7/29/2026 | $0 |
| | 2026 | 2026 | JOSLIN DIABETES CENTER, INC. | 330 BROOKLINE AVE | BOSTON | MA | 02215-5400 | SUFFOLK | USA | U01DK116102 | 9/14 APOL1 Long-term Kidney Transplantation Outcomes Network (APOLLO) Clinical Center | 001 | 8 | NIH | 7/14/2026 | $27,273 |
| | 2026 | 2026 | JOSLIN DIABETES CENTER, INC. | 330 BROOKLINE AVE | BOSTON | MA | 02215-5400 | SUFFOLK | USA | U01DK116102 | 9/14 APOL1 Long-term Kidney Transplantation Outcomes Network (APOLLO) Clinical Center | 001 | 8 | NIH | 7/14/2026 | $23,077 |
| | 2026 | 2026 | JOSLIN DIABETES CENTER, INC. | 330 BROOKLINE AVE | BOSTON | MA | 02215-5400 | SUFFOLK | USA | U01DK116102 | 9/14 APOL1 Long-term Kidney Transplantation Outcomes Network (APOLLO) Clinical Center | 001 | 8 | NIH | 7/14/2026 | $167,031 |
| | 2026 | 2026 | JOSLIN DIABETES CENTER, INC. | 330 BROOKLINE AVE | BOSTON | MA | 02215-5400 | SUFFOLK | USA | U01DK134996 | Understanding, Predicting and Preventing Type 2 Diabetes in Youth, Boston Clinical Center (UPP Study) | 001 | 4 | NIH | 8/10/2026 | $663,241 |
| | 2026 | 2026 | JOSLIN DIABETES CENTER, INC. | 330 BROOKLINE AVE | BOSTON | MA | 02215-5400 | SUFFOLK | USA | U01DK116102 | 9/14 APOL1 Long-term Kidney Transplantation Outcomes Network (APOLLO) Clinical Center | 002 | 8 | NIH | 7/29/2026 | $0 |
| | 2026 | 2026 | JOSLIN DIABETES CENTER, INC. | 330 BROOKLINE AVE | BOSTON | MA | 02215-5400 | SUFFOLK | USA | R25DK140752 | Joslin-BIDMC Postbac Program in Diabetes and Metabolism | 000 | 3 | NIH | 8/7/2026 | $397,444 |
| | 2026 | 2026 | JOSLIN DIABETES CENTER, INC. | 330 BROOKLINE AVE | BOSTON | MA | 02215-5400 | SUFFOLK | USA | RC2DK139552 | Epitranscriptomics in human obesity and type 2 diabetes | 001 | 3 | NIH | 7/24/2026 | $1,968,589 |
| | 2026 | 2026 | JOSLIN DIABETES CENTER, INC. | 1 JOSLIN PL | BOSTON | MA | 02215-5306 | SUFFOLK | USA | R01NS135175 | Modulating the adaptive immune response to enhance the efficiency of in vivo gene editing in muscle | 000 | 3 | NIH | 6/23/2026 | $545,534 |
| | 2026 | 2026 | JOSLIN DIABETES CENTER, INC. | 330 BROOKLINE AVE | BOSTON | MA | 02215-5400 | SUFFOLK | USA | R01DK137518 | Glucagon Pump Therapy for Post-Bariatric Hypoglycemia: Merging Physiology and Engineering | 000 | 4 | NIH | 7/9/2026 | $709,250 |
| | 2026 | 2026 | JOSLIN DIABETES CENTER, INC. | 1 JOSLIN PL | BOSTON | MA | 02215-5306 | SUFFOLK | USA | R01DK132535 | Elucidating and targeting beta-cell senescence and its SASP | 000 | 5 | NIH | 3/31/2026 | $427,500 |
| | 2026 | 2026 | JOSLIN DIABETES CENTER, INC. | 1 JOSLIN PL | BOSTON | MA | 02215-5306 | SUFFOLK | USA | R01DK129850 | Gut microbial fermentation products of muscle-derived lactate as mediators of exercise and metabolism | 000 | 5 | NIH | 5/12/2026 | $568,630 |
| | 2026 | 2026 | JOSLIN DIABETES CENTER, INC. | 1 JOSLIN PL | BOSTON | MA | 02215-5306 | SUFFOLK | USA | R01HL161858 | Early myocardial remodeling and progressive kidney function decline in type 1 diabetes | 000 | 5 | NIH | 3/20/2026 | $828,756 |
| | 2026 | 2026 | JOSLIN DIABETES CENTER, INC. | 1 JOSLIN PL | BOSTON | MA | 02215-5306 | SUFFOLK | USA | R01DK132469 | Transcriptional and epigenetic regulation of thermogenic adipocyte program | 000 | 5 | NIH | 4/7/2026 | $602,295 |
| | 2026 | 2026 | JOSLIN DIABETES CENTER, INC. | 1 JOSLIN PL | BOSTON | MA | 02215-5306 | SUFFOLK | USA | R01HD117197 | Maternal exercise during lactation to ignite infant metabolism | 000 | 2 | NIH | 4/2/2026 | $631,027 |
| | 2026 | 2026 | JOSLIN DIABETES CENTER, INC. | 330 BROOKLINE AVE | BOSTON | MA | 02215-5400 | SUFFOLK | USA | T32DK007260 | Training Grant in Diabetes and Metabolism | 000 | 50 | NIH | 7/3/2026 | $1 |
| | 2026 | 2026 | JOSLIN DIABETES CENTER, INC. | 1 JOSLIN PL | BOSTON | MA | 02215-5306 | SUFFOLK | USA | R01DK067536 | Role of IGF-1 and insulin receptors beta-cell survival | 000 | 19 | NIH | 12/5/2025 | $703,778 |
| | 2026 | 2026 | JOSLIN DIABETES CENTER, INC. | 1 JOSLIN PL | BOSTON | MA | 02215-5306 | SUFFOLK | USA | R01DK082659 | Developmental genes, miRNAs and adipose tissue | 000 | 18 | NIH | 4/7/2026 | $701,100 |
| | 2026 | 2026 | JOSLIN DIABETES CENTER, INC. | 1 JOSLIN PL | BOSTON | MA | 02215-5306 | SUFFOLK | USA | R01DK031036 | Insulin Receptor Structure and Turnover | 000 | 44 | NIH | 2/27/2026 | $866,374 |
| | 2026 | 2026 | JOSLIN DIABETES CENTER, INC. | 1 JOSLIN PL | BOSTON | MA | 02215-5306 | SUFFOLK | USA | R01DK101043 | Exercise Regulation of Glucose Homeostasis | 000 | 28 | NIH | 4/27/2026 | $687,200 |
| | 2026 | 2026 | JOSLIN DIABETES CENTER, INC. | 1 JOSLIN PL | BOSTON | MA | 02215-5306 | SUFFOLK | USA | R01DK099511 | Novel Mechanisms of Exercise Training Effects on Glucose Homeostasis | 000 | 12 | NIH | 12/29/2025 | $716,991 |
| | 2026 | 2026 | JOSLIN DIABETES CENTER, INC. | 330 BROOKLINE AVE | BOSTON | MA | 02215-5400 | SUFFOLK | USA | U01DK142331 | Characterization of risk factors for excessive cardiovascular diseases (CVD) from circulating and cardiovascular tissues of people with well-controlled chronic type 1 diabetes | 001 | 3 | NIH | 8/4/2026 | $849,124 |
| | 2026 | 2026 | JOSLIN DIABETES CENTER, INC. | 330 BROOKLINE AVE | BOSTON | MA | 02215-5400 | SUFFOLK | USA | U01DK140790 | Identifying Targets for Preventing Neurocognitive Complications in Youth with T1D | 000 | 3 | NIH | 8/17/2026 | $631,247 |
| | 2026 | 2026 | JOSLIN DIABETES CENTER, INC. | 1 JOSLIN PL | BOSTON | MA | 02215-5306 | SUFFOLK | USA | P30DK036836 | Diabetes Research Center | 000 | 40 | NIH | 5/5/2026 | $1,706,072 |
| | 2026 | 2026 | JOSLIN DIABETES CENTER, INC. | 1 JOSLIN PL | BOSTON | MA | 02215-5306 | SUFFOLK | USA | R01DK137511 | Lipotoxicity and Maintenance of Metabolic Health | 000 | 4 | NIH | 4/1/2026 | $597,775 |
| | 2026 | 2026 | JOSLIN DIABETES CENTER, INC. | 1 JOSLIN PL | BOSTON | MA | 02215-5306 | SUFFOLK | USA | R01DK138605 | Translational Programming of Beta-cells in Response to Glucose Toxicity | 000 | 3 | NIH | 6/9/2026 | $694,309 |
| | 2026 | 2025 | JOSLIN DIABETES CENTER, INC. | 1 JOSLIN PL | BOSTON | MA | 02215-5306 | SUFFOLK | USA | R35GM122610 | Signaling mechanisms that detect stress and maintain homeostasis | 000 | 9 | NIH | 12/8/2025 | $0 |
| | 2026 | 2025 | JOSLIN DIABETES CENTER, INC. | 330 BROOKLINE AVE | BOSTON | MA | 02215-5400 | SUFFOLK | USA | R01DK128429 | Alterations in Post-Receptor Insulin Signaling in Diabetes and Insulin Resistance | 000 | 5 | NIH | 5/4/2026 | $0 |
| | 2026 | 2025 | JOSLIN DIABETES CENTER, INC. | 330 BROOKLINE AVE | BOSTON | MA | 02215-5400 | SUFFOLK | USA | U01DK134996 | Understanding, Predicting and Preventing Type 2 Diabetes in Youth, Boston Clinical Center (UPP Study) | 000 | 3 | NIH | 7/31/2026 | $0 |
| | 2026 | 2025 | JOSLIN DIABETES CENTER, INC. | 330 BROOKLINE AVE | BOSTON | MA | 02215-5400 | SUFFOLK | USA | K99DK140526 | Pancreatic beta-cell glucose toxicity and mRNA translation | 001 | 2 | NIH | 6/5/2026 | $0 |
| | 2026 | 2025 | JOSLIN DIABETES CENTER, INC. | 1 JOSLIN PL | BOSTON | MA | 02215-5306 | SUFFOLK | USA | K99DK140526 | Pancreatic beta-cell glucose toxicity and mRNA translation | 000 | 2 | NIH | 5/8/2026 | $0 |
| | 2026 | 2025 | JOSLIN DIABETES CENTER, INC. | 330 BROOKLINE AVE | BOSTON | MA | 02215-5400 | SUFFOLK | USA | RC2DK139552 | Epitranscriptomics in human obesity and type 2 diabetes | 000 | 2 | NIH | 7/15/2026 | $0 |
| | 2026 | 2025 | JOSLIN DIABETES CENTER, INC. | 330 BROOKLINE AVE | BOSTON | MA | 02215-5400 | SUFFOLK | USA | U01DK135095 | Using ex vivo, in vivo models and patient mutations to interrogate pancreatic exocrine-endocrine cross talk | 000 | 4 | NIH | 4/30/2026 | $0 |
| | 2026 | 2025 | JOSLIN DIABETES CENTER, INC. | 330 BROOKLINE AVE | BOSTON | MA | 02215-5400 | SUFFOLK | USA | R01DK131061 | Causal connections between axon guidance proteins and early progressive kidney function decline in diabetes | 000 | 4 | NIH | 12/9/2025 | $0 |
| | 2026 | 2025 | JOSLIN DIABETES CENTER, INC. | 330 BROOKLINE AVE | BOSTON | MA | 02215-5400 | SUFFOLK | USA | R01DK133528 | Dissecting the thermogenic adipose niche | 000 | 4 | NIH | 8/20/2026 | $0 |
| | 2026 | 2025 | JOSLIN DIABETES CENTER, INC. | 330 BROOKLINE AVE | BOSTON | MA | 02215-5400 | SUFFOLK | USA | R01HL161864 | Characterization of cardiovascular diseases (CVD) in people with long duration Type 1 diabetes | 000 | 4 | NIH | 5/20/2026 | $0 |
| | 2026 | 2025 | JOSLIN DIABETES CENTER, INC. | 1 JOSLIN PL | BOSTON | MA | 02215-5306 | SUFFOLK | USA | R35GM122610 | Signaling mechanisms that detect stress and maintain homeostasis | 001 | 9 | NIH | 2/6/2026 | $0 |
| | 2026 | 2025 | JOSLIN DIABETES CENTER, INC. | 1 JOSLIN PL | BOSTON | MA | 02215-5306 | SUFFOLK | USA | U01DK142331 | Characterization of risk factors for excessive cardiovascular diseases (CVD) from circulating and cardiovascular tissues of people with well-controlled chronic type 1 diabetes | 000 | 2 | NIH | 4/7/2026 | $0 |
| | 2026 | 2024 | JOSLIN DIABETES CENTER, INC. | 1 JOSLIN PL | BOSTON | MA | 02215-5306 | SUFFOLK | USA | U01DK116102 | 9/14 APOL1 Long-term Kidney Transplantation Outcomes Network (APOLLO) Clinical Center | 000 | 6 | NIH | 3/27/2026 | $0 |
| | 2026 | 2024 | JOSLIN DIABETES CENTER, INC. | 1 JOSLIN PL | BOSTON | MA | 02215-5306 | SUFFOLK | USA | U01DK116102 | 9/14 APOL1 Long-term Kidney Transplantation Outcomes Network (APOLLO) Clinical Center | 000 | 6 | NIH | 3/27/2026 | $0 |
| | 2026 | 2024 | JOSLIN DIABETES CENTER, INC. | 1 JOSLIN PL | BOSTON | MA | 02215-5306 | SUFFOLK | USA | U01DK116102 | 9/14 APOL1 Long-term Kidney Transplantation Outcomes Network (APOLLO) Clinical Center | 000 | 6 | NIH | 3/27/2026 | $0 |
|
